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was observed. After 6 weeks of treatment, no statistically significant difference
between time periods was observed for the HAM-D21 and HAM-D17, although
a trend was observed (P<0.103) in a LOCF analysis. For HAM-D6, a difference
was observed in the LOCF analysis between Apr-Sep and Oct-Dec (P<0.05).
Conclusion: These preliminary results suggest that exploring the effect of
season may be informative for the conduct of clinical trials in depression and for
the choice of assessment scales. Further investigation of this effect is warranted.
Funding Source: Wyeth Research
(1) Hamilton M (1967) Development of a rating scale for primary depressive
illness. British Journal of Social and Clinical Psychology 6: 278–296.
(2) Bech P, Allerup P, Gram F, Reisby N, Rosenberg R, Jacobsen O, Nagy
A (1981) The Hamilton Depression Scale: evaluation of objectivity using
logistic models. Acta Psychiatrica Scandinavica 63: 290–299.
P01.128 ANGER ATTACKS IN SEASONAL AFFECTIVE DISORDER
D. Winkler, E. Pjrek, A. Konstantinidis, N. Praschak-Rieder, M. Willeit, A. Hei-
den, S. Kasper. Medical University of Vienna, Austria
Statement of the Study: It has been proposed that aggression and especially
anger attacks (sudden spells of anger with vegetative hyperarousal) play an
important role in the symptomatology of depression (Fava et al., 1990). The
aim of the present study was to assess the prevalence of anger attacks in a
clinical sample of patients with seasonal affective disorder (SAD).
Methods: 30 outpatients (20 females and 10 males aged 39.3±13.4 years)
with SAD according to the diagnostic criteria of the DSM-IV were included
in this evaluation. The sample mean of the global seasonality score (GSS)
as measured by the seasonal pattern assessment questionnaire (SPAQ) was
15.0±2.4. Subjects with subsyndromal SAD were excluded from the study.
Anger attacks were assessed with the Anger Attacks Questionnaire (Fava et al.,
1991).
Summary of Results: 83.3% of our patients had higher levels of irritability
as compared to their non-depressed state. 11 subjects (36.7%) were classified as
suffering from anger attacks. Interestingly males (50.0%) reported having anger
attacks more frequently than females (30.0%), however our sample was too small
to yield a statistically significant difference between the two genders (Fisher’s
Exact Test (two-sided): p=0.425).
Conclusion: As previously reported for non-seasonal depression, anger attacks
play an important role in the clinical picture of SAD. Replication of our results
in larger samples has to be carried out to prove the hypothesis of sex differences
in the prevalence of anger attacks in SAD.
Fava M, Anderson K, Rosenbaum JF (1990). “Anger attacks”: Possible variants
of panic and major depressive disorder. Am J Psychiatry 147:867–870.
Fava M, Rosenbaum JF, McCarthy M, Pava J, Steingard R, Bless E (1991).
Anger attacks in depressed outpatients and their response to fluoxetine.
Psychopharmacol Bull 27: 275–279.
P01.129 USING TREATMENT ALGORITHMS TO ACHIEVE
REMISSION OF DEPRESSION WITH VENLAFAXINE XR
OR SSRIs
I. Benattia1, J. Musgnung2, J. Graepel1. 1Wyeth Research, USA; 2Wyeth Phar-
maceuticals, USA
Statement of the Study: This study was designed to compare remission rates
among patients with major depressive disorder (MDD) treated with venlafaxine
extended release (XR) or selective serotonin reuptake inhibitors (SSRIs) using
treatment algorithms and length of treatment guidelines.
Methods: In this open-label, rater-blinded, multicenter study, outpatients with
MDD and a 17-item Hamilton Rating Scale for Depression (HAM-D17) total
score of at least 20 were randomly assigned to receive treatment with flexible
doses of venlafaxine XR (75–225 mg/day; n=688) or an SSRI selected by
the investigator (n=697 [fluoxetine (20–80 mg/day; n=114), paroxetine (20–
50 mg/day; n=131), citalopram (20–40 mg/day; n=159), or sertraline (50–
200 mg/day; n=193)]) for up to 180 days. Treatment was initiated at the lowest
effective dose, with dose increases permitted at days 30 and 60 based on treatment
response and dosing guidelines (maximum allowable doses were the upper limit
of the Food and Drug Administration–approved dose ranges for depression).
Remission was defined as a HAM-D17 total score <8.
Summary of Results: Mean maximum prescribed doses were venlafaxine XR
157 mg/day, fluoxetine 55 mg/day, paroxetine 41 mg/day, citalopram 35 mg/day,
and sertraline 135 mg/day. Remission rates (intent-to-treat population; last
observation carried forward) were significantly greater in the venlafaxine XR
group versus the SSRI group at days 30 (13% vs 9%), 60 (23% vs 18%), 90 (29%
vs 24%), and 135 (33% vs 27%) (P<0.05 for all comparisons). Day 180 remission
rates were 35.5% and 32% for venlafaxine XR and SSRIs, respectively (P=NS).
Individual SSRI remission rates at day 180 were fluoxetine 36%, paroxetine 28%,
citalopram 31%, and sertraline 33%.
Conclusion: These results suggest that venlafaxine XR is an effective treat-
ment for MDD, and may bring patients to remission earlier in treatment compared
with SSRIs when treatment algorithms and guidelines for duration of therapy are
used.
P01.130 OREON: OBSERVATION OF REMISSION IN DEPRESSION
IN PRIMARY AND PSYCHIATRIC CARE
M. Ansseau1, K. Demyttenaere2, J. Heyrman3, A. Migeotte4, S. Leyman5,
A. Mignon5. 1Liège University Hospital, Belgium; 2University Hospital
Gasthuisberg, Belgium; 3KUL, Belgium; 4Liège University, Belgium; 5WYETH,
Belgium
Statement of the Study: Treatment of depression should result in absence of
symptoms i.e. remission, to restore the functional state of the patient and reduce
the risk of relapse (Keller et al, 2003). OREON aims to determine remission rates
in patients treated for depression in primary and psychiatric care. Remission rates
will be correlated with functional status, type of treatment and socio-economic
factors.
Methods: GP’s and psychiatrists each screened 10 consecutive patients treated
for depression since at least 3 months and not more than 12 months. Remission
rates were measured using the HAM-D 7 item (McIntyre et al, 2002) in primary
care and HAM-D 17 in psychiatry. Patients completed the Sheehan Disability
Scale and the Carroll rating scale. Initial severity of depression, type of treatment
and socio-economic factors were collected.
Summary of Results: 300 GP’s and 60 psychiatrists screened a total of 3600
patients. Results showed that remission rates were low in patients treated for
depression. Absence of remission was associated with higher disability. Data are
analysed to assess whether type of treatment and socio-economic factors impact
on remission rates.
Conclusion: OREON is the first study to show remission rates in patients
treated for depression in a naturalistic setting in primary and psychiatric care.
Many patients present important levels of residual symptoms.
P01.131 ARE GENDER DIFFERENCES IN ANTIDEPRESSANT
RESPONSE SPECIFIC TO SEROTONINERGIC AGENTS?
A COMPARATIVE STUDY OF CITALOPRAM vs.
REBOXETINE
C. Berlanga, M. Flores. National Institute of Psychiatry Dr. Ramón de la Fuente,
Mexico
Statement of the Study: Prevalence of major depression is higher in women than
in men, especially in premenopausal years. Gender differences are also reported
in treatment outcome with antidepressants. Most although not all studies find that
compared to postmenopausal women or men, young women respond better to
selective serotonin reuptake inhibitors (SSRI). However many studies have used
only non-selective antidepressants as comparative drugs. The purpose of our trial
was to replicate these reports comparing two radical different drugs: reboxetine
(RBX) a specific selective noradrenaline reuptake inhibitor and citalopram (CTP)
the most specific SSRI drug.
Methods: During an 8-week double-blind trial including 86 drug-free de-
pressed outpatients (DSM-IV criteria), 19 male and 25 female patients received
CTP(20–40 mg/d), while 19 and 23 respectively received RBX (4–8 mg/d).
Response was evaluated with the 21-item Hamilton Depression Rating Scales
(HDRS), and side-effects were registered using a pre-designed instrument. All
participating women were premenopausal. Results were analyzed by a 2×2 Anal-
ysis of Variance (ANOVA) evaluating interactions between gender, response and
time.
Summary of Results: No significant differences in age or other sociode-
mographic variables were found when splitting total group according to gender
and drug assignment. Mean HDRS basal score was similar across groups and
at the end of the study its mean point reduction (±SD) resulted as follows:
women −17.2±2.0 (CTP) and −12.7±1.2 (RBX); men −14.0±2.2 (CTP) and
−15.6±2.0 (RBX). Both drugs were well tolerated and no gender differences for
adverse events were found.
Conclusion:Women showed a greater response to CTP than to RBX, while in
men these differences were not observed (F=4.65; df=3; p=0.005). As all women
included in the study were premenopausal (<42 years of age), our findings
support the concept that estrogens, interacting in the brain mainly with the
serotoninergic system, may enhance the antidepressant effect. Additionally, by
